MedPath

Retrospective study of elderly patients with classical Hodgkin lymphoma in Japan: HORIZON study

Not Applicable
Conditions
Classical Hodgkin lymphoma
Registration Number
JPRN-UMIN000033264
Lead Sponsor
HORIZON study investigators
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
171
Inclusion Criteria

Not provided

Exclusion Criteria

1) Positive for HIV 2) Patients who received first-line treatment outside the study institution 3) Patients who were not treated or managed by the hematologists in each study institution (ex. Second opinion) 4) Patients who were diagnosed as having methotrexate-associated lymphoproliferative disorders.

Study & Design

Study Type
Others,meta-analysis etc
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
5-year overall survival rate
Secondary Outcome Measures
NameTimeMethod
1) 5-year progression-free survival rate 2) 5-year event-free survival rate 3) Overall response rate and complete response rate of first-line therapy 4) The rate of bleomycin lung toxicity (BLT) 5) The rate of patients who completed 100%-dose ABVD therapy 6) The average relative dose-intensity of ABVD therapy 7) Charlson Comorbidity Index (CCI) score at the baseline 8) Investigation of pathological biomarkers
© Copyright 2025. All Rights Reserved by MedPath